wr 1065 has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZJ; Hopper, E; Murphy, M; Shen, H; Tew, KD; Zilfou, JT | 1 |
| Berlion, M; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C | 1 |
2 other study(ies) available for wr 1065 and Malignant Melanoma
| Article | Year |
|---|---|
Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoprotection; Electrophoresis, Polyacrylamide Gel; Fibroblasts; HeLa Cells; Humans; Melanoma; Mercaptoethylamines; Mice; NF-kappa B; NF-kappa B p50 Subunit; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-mdm2; Transcription Factor AP-1; Transcription Factors; Transcriptional Activation; Tumor Suppressor Protein p53 | 2001 |
Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Drug Synergism; Humans; Inhibitory Concentration 50; Melanoma; Mercaptoethylamines; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Radiation-Protective Agents; Tumor Cells, Cultured | 2002 |